Dec 17, 2021
Notice of Board of Director’s Resolution on Application for New Market Segment “Prime Market”
| Name of listed company: | Chugai Pharmaceutical Co., Ltd. |
| Code number: | 4519 (1st Section of Tokyo Stock Exchange) |
| Head office: | 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo |
| President & CEO: | Osamu Okuda |
| Inquiries to: | Toshiya Sasai |
| Head of Corporate Communications Dept. | |
| Tel:+81-(0)3-3273-0554 |
Chugai Pharmaceutical Co., Ltd. (hereafter the “Company”) announces that the Company resolved at the meeting of its Board of Directors held today, to apply for listing on the “Prime Market,” one of the new market segments of the Tokyo Stock Exchange (TSE).
On July 9, 2021, the Company received the notice of initial assessment by the TSE, confirming that it is in compliance with the continued listing criteria for the Prime Market in the new market segments.
The Company will follow the prescribed procedures related to the application for the selection of the new market segments in accordance with the schedule set by the TSE.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Tomoko Shimizu
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
